Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, PK and PD of MK0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK0941 Before Each Meal in Subjects With T2D Being Treated With Basal Insulin.

Trial Profile

Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, PK and PD of MK0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK0941 Before Each Meal in Subjects With T2D Being Treated With Basal Insulin.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2012

At a glance

  • Drugs MK 0941 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2011 Acutal patient number (70) reported at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 07 Apr 2009 Actual patient number (66) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top